OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Organization: Amoneta Diagnostics

2 Projects | 1 Researchers | $3,592,026 Invested

2022

Amoneta Diagnostics

Hueseyin FIRAT, MD, PhD

Validation of MemoryLinc test’s blood ncRNAs for detection of early AD and monitoring its progression and for monitoring the responses of anti-amyloid therapeutic strategies on samples from participants with prodromal to mild AD and having Amyloid CSF or PET positivity (Amoneta follow on funding)

  • Funding Amount: $1,592,026
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Closed

2019

Amoneta Diagnostics

Hueseyin FIRAT, MD, PhD

Validation of a rapid non-invasive diagnostic test to predict mild cognitive impairment and early Alzheimer’s disease

  • Funding Amount: $2,000,000
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Closed